Cardiology Pharmacy Specialty Certification (BCCP)
Target Population: Pharmacists who specialize in the optimization of patient care by
ensuring safe and effective use of medications in patients with or at risk
for cardiovascular disease.
Program Purpose: To validate that the pharmacist has the advanced knowledge, skills, and
experience to optimize patient outcomes and cardiovascular health by
focusing on the prevention and treatment of cardiovascular disease.
Currently, there are more than 870 BPS Board-Certified Cardiology Pharmacists.
Important BCCP Exam Update
The Board-Certified Cardiology Pharmacist (BCCP) certification and recertification examinations will transition from continuous testing to a scheduled testing window in 2026.
2026 Continuous Testing (Limited Availability)
Registration: January 20–February 7, 2026
Sit for an Exam until: March 31, 2026
2026 Windowed Testing
Registration: February 8–August 17, 2026
Testing window: September 1–21, 2026
Candidates who test during Q1 2026 and do not pass may plan to retake the BCCP examination during the September 2026 testing window, subject to eligibility.
Cardiology Pharmacy Specialty Council Members
The purpose of the BPS Specialty Councils is to develop standards and eligibility requirements for board certification, develop examinations and passing standards for certification, and review and approve professional development programs for recertification of board-certified pharmacists. Specialty council members are at the heart of the peer-reviewed and peer-developed nature of BPS Board Certification.
Marrs is a Cardiology Ambulatory Clinical Pharmacist with the Heart and Vascular Institute at Cheyenne Regional Medical Group. Additionally, he is a Clinical Associate Professor at the University of Colorado School of Medicine. He received his Doctor of Pharmacy degree from Butler University and Master of Public Health degree from the University of Colorado. He completed a PGY1 residency at Mount Carmel Medical Center and a PGY2 Ambulatory Care Residency at the University of Colorado. He has extensive pharmacy faculty and clinical pharmacy practice experience in ambulatory care, with a focus on cardiology & cardiometabolic diseases. His research interests are focused on the prevention and management of endocrine and cardiovascular disease and patient centered outcomes research.
Katherine Crawford is the lead Cardiology Pharmacist at OhioHealth Riverside Methodist Hospital. She graduated from The Ohio State University College of Pharmacy and completed both a PGY1 pharmacy practice residency and PGY2 critical care pharmacy residency at OhioHealth Riverside Methodist Hospital. Her professional interests include acute coronary syndromes, heart failure, anticoagulation, and teaching. She provides clinical pharmacy services to the cath lab, serves as a pharmacy representative on the OhioHealth Heart and Vascular Clinical Guidance Council, and enjoys facilitating multidisciplinary discussions about updates in cardiology and incorporation of new research into practice.
Kyle Bergen is a Clinical Pharmacy Specialist in Cardiac Critical Care and Cardiac Surgery at Orlando Health Orlando Regional Medical Center. He graduated with his BSPS and PharmD from the University of Toledo College of Pharmacy and Pharmaceutical Sciences and completed PGY-1 pharmacy and PGY-2 cardiology pharmacy residencies at AdventHealth Orlando. After residency, he practiced at Northwestern Memorial Hospital in Chicago, Illinois, working closely with the advanced heart failure and cardiac surgery service lines. Upon returning to Orlando, he is working to grow pharmacy presence with the same services. His clinical and research interests include heart failure, mechanical circulatory support, cardiac surgery, and anticoagulation.
Danielle Blais is the Lead Cardiology Specialty Practice Pharmacist at the Richard M. Ross Heart Hospital at The Ohio State University Wexner Medical Center. She received her Doctor of Pharmacy degree from SUNY Buffalo. She is board certified in pharmacotherapy and cardiology. She serves as a Clinical Assistant Professor at The Ohio State University College of Pharmacy. In addition to her adjunctive appointment at the College, she maintains an active clinical practice in the areas of acute coronary syndromes and treatment of venous thromboembolism, as well as provides pharmacy services to the Cardiac Catheterization Lab. At the OSUWMC, she has served on multiple quality committees including the Interventional and Medical Cardiology Operations Council and has worked extensively on developing treatment protocols in these areas. She is one of the Project Leaders for the Clinical Process Improvement Medication Reconciliation Charter for the OSUWMC Health System.
Heidi is the Clinical Pharmacy Supervisor of Cardiology and Cardiothoracic Transplant at Nebraska Medicine. She also serves as the program director for the PGY2 Cardiology residency program and holds an adjunct appointment at the University of Nebraska Medical Center College of Pharmacy (UNMC). Brink received her Doctor of Pharmacy degree from UNMC and then went on to complete her PGY1 Pharmacy Practice and PGY2 Cardiology residencies at The Ohio State University Wexner Medical Center. After completing her training, she returned home to Nebraska Medicine and now serves as the Pharmacist Specialist for the Advanced Decompensated Heart Failure/Heart Transplant and Lung Transplant teams.
Maria Coyle, PharmD, FCCP, BCPS, BCACP, CLS is a Professor-Clinical at The Ohio State University in Columbus Ohio, where she also received her Bachelor of Science and Doctor of Pharmacy degrees. She joined the faculty in 2002, after completing post-graduate fellowship training in nephrology and clinical pharmacokinetics.
Dr. Coyle is an ambulatory care pharmacy specialist at Ohio State’s Wexner Medical Center. Areas of interest include lipid management and cardiac risk prevention, chronic kidney disease, and associated chronic conditions. She has been extensively involved in research and teaching preparation for residency/ post-graduate programs in the College of Pharmacy and served as inaugural faculty fellow in the University’s Drake Institute for Teaching and Learning. Her scholarly interests include research in ambulatory care practice, and faculty training and support.
Fanous is a clinical pharmacy specialist in cardiology at the University of California San Francisco (UCSF) Medical Center. He also serves as a volunteer clinical associate professor at the UCSF College of Pharmacy. He received his Bachelor’s degree in pharmacy from the University of Cairo in Egypt, and his Doctor of Pharmacy degree from the University of Florida. His clinical focus is on pulmonary hypertension, advanced heart failure, acute coronary syndrome, and cardiac arrhythmia.
Knowles is a Clinical Pharmacy Specialist in Cardiology with Kaiser Permanente Georgia and her practice focuses on ambulatory heart failure management, population health, and transitions of care. After receiving her PharmD from the University of Florida, she completed both her PGY1 Pharmacy Practice and PGY2 Ambulatory Care residencies at the James A. Haley VA.
Andrew Smith is a Clinical Professor in the Division of Pharmacy Practice and Administration at the University of Missouri at Kansas City (UMKC) School of Pharmacy. He has over twenty years of experience in acute care cardiology practice, most recently at University Health in Kanas City MO. He received his PharmD from the UMKC and completed his PGY1 residency at the VA Medical Center in Iowa City, IA. Andrew has published numerous papers, abstracts, and book chapters focused on cardiovascular pharmacotherapy. His professional interests include heart failure pharmacotherapy, improving adherence with cardiac rehabilitation, and cardiovascular care in the under-served.
Rhynn Soderstrom PharmD, BCPS, BCCP, AACC is an anticoagulation pharmacy specialist who has transitioned from adult cardiac surgery at Brigham and Women’s Hospital in Boston to pediatric cardiology at Children’s Hospital Colorado in Denver. She most recently has transitioned for pediatric critical care cardiology to an anticoagulation specialist at Children’s Colorado. She completed her PGY-1 at Northwestern Medicine in Chicago, IL and her PGY-2 in Cardiology at UMASS Memorial Medical Center in Worcester, MA. She was the PGY-2 Cardiology Residency Coordinator at Brigham and Women’s Hospital from 2016-2019 and took over as the residency director in 2020 before moving to Denver and tackling pediatric cardiology. She is currently a residency program coordinator for the PGY-1 Residency Program at Children’s. Her research interests include anticoagulation and heart failure and she is continues to work closely with the adult congenital heart disease team at Children’s Hospital Colorado.
Thomas Szymanski is a clinical pharmacist specialist in cardiovascular surgery and cardiology at Baylor St. Luke’s Medical Center in Houston, TX. He rounds in the Cardiovascular Recovery Room at the Texas Heart Institute, where he manages post-surgical patients in one of the sickest ICUs in the country. He received his PharmD and BA in French from the University of Rhode Island and completed his PGY1 pharmacy and PGY2 cardiology pharmacy residencies at Memorial Hermann – Texas Medical Center in Houston, TX. After residency, he practiced at West Virginia University Medicine – J.W. Ruby Memorial Hospital as a clinical pharmacy specialist in cardiovascular critical care. Thomas’s practice and research interests include heparin-induced thrombocytopenia, antiplatelet therapy in acute coronary syndromes, and valvular heart disease.
Dr. Talasaz is a Heart Failure Manager at NewYork-Presbyterian/Columbia University Medical Center and an Adjunct Faculty member at Virginia Commonwealth University (VCU) in Richmond, VA. Her professional interests focus on heart failure and antithrombotic management in cardiovascular disease.
She previously served as a tenured professor in the Department of Clinical Pharmacy at Tehran University of Medical Sciences and at the Tehran Heart Center in Iran. Dr. Talasaz earned her Doctor of Pharmacy degree and completed a four-year Clinical Pharmacy Residency in Iran, followed by a Fellowship in Intensive Care Unit (ICU) Pharmacotherapy and an Experimental Cardiovascular Pharmacotherapy Research Fellowship at VCU.
Eligibility Requirements for BCCP®
An applicant for board certification in Cardiology Pharmacy must demonstrate all of the eligibility requirements listed below. All practice and education eligibility requirements must be met before submitting the application. Once all of the requirements below are met, an applicant will be deemed eligible to sit for the Cardiology Pharmacy specialty certification examination. If an applicant achieves a passing score on the Cardiology Pharmacy specialty certification examination, they may use the designation Board-Certified Cardiology Pharmacist, or BCCP®.
Refer to the Cardiology Pharmacy Examination Content Outline here for details on eligibility requirements, effective dates, and more.
The rationale for the appropriateness of the requirements for BPS certification programs are based upon the following:
- BPS recognizes individuals who graduate from a recognized school or college of pharmacy within the candidate’s jurisdiction. Those jurisdictions recognize and evaluate programs on the extent to which it accomplishes its stated goals and is consistent with the concept that pharmacy is a unique, personal service profession in the health science field. In the United States, the responsibility for recognizing schools and colleges of pharmacy falls to the Accreditation Council for Pharmacy Education (ACPE).
- The rationale for requiring licensure or registration of pharmacists within their jurisdiction is based upon the fact that for public protection, all pharmacists must be licensed or registered. This is considered a baseline requirement to be a pharmacist specialist. In the United States, BPS recognizes the licensure process administered by the National Association of Boards of Pharmacy (NABP). The National Association of Boards of Pharmacy (NABP) aims to ensure the public’s health and safety through its pharmacist license transfer and pharmacist competence assessment programs. NABP’s member boards of pharmacy are grouped into eight districts that include all 50 United States, the District of Columbia, Guam, Puerto Rico, the Virgin Islands, Bahamas, and all 10 Canadian provinces.
- The experiential component is required to help assure practical application of components of the specialty knowledge being certified. There are multiple pathways to meet the practice experience requirement. The faster eligibility pathways recognize accredited residencies through the American Society of Health System Pharmacists (ASHP). The ASHP residency accreditation program identifies and grants public recognition to practice sites having pharmacy residency training programs that have been evaluated and found to meet the qualifications of one of the ASHP’s residency accreditations standards. Thus, accreditation of a pharmacy residency program provides a means of assurance to residency applicants that a program meets certain basic requirements and is, therefore, an acceptable site for postgraduate training in pharmacy practice in organized health care.
- Passing the BPS pharmacy specialty examination helps assure knowledge consistent with the validated content outline for the BPS specialty.
The appropriateness of the BPS program requirements are consistent with the Council on Credentialing in Pharmacy’s Resource Paper titled: Scope of Contemporary Pharmacy Practice: Roles, Responsibilities, and Functions of Pharmacists and Pharmacy Technicians.
Upcoming Deadlines for Certification Examinations
Individuals who meet the eligibility requirements for the BCCP examination can find more information about examination dates and fees for certification examinations here.
Candidate's Guide
The Candidate’s Guide is intended for use by pharmacists who are interested in becoming certified as specialists by BPS in any of the BPS-recognized specialty practice areas. To review critical information for BPS Certification Examinations, visit this page.
Content Outline for BCCP Examinations
- Refer to the Cardiology Pharmacy Examination Content Outline here for details on eligibility requirements, effective dates, and more.
The examination content outline is a product of a job analysis, also known as a role delineation study, that includes discussions with a panel of 15-20 subject matter experts who represent the specialty area. These experts determine the competencies required for safe and effective pharmacy practice in the specialty area and engage board-certified pharmacists through a validation survey for their endorsement of the identified competencies. The job analysis process is conducted every 5 years to help ensure that the competencies in the examination content outline reflect current pharmacy practice in the specialty area.
- Click here to review the 2025 BCCP Job Analysis Summary.
Important Resources
Preparing for the BCCP® Examination
Certification is a significant differentiator, and the rigorous exam process requires concentrated study. Successful candidates are well prepared, and a number of available resources can assist pre-qualified applicants.
Suggested preparation for the examination might include:
- The study of journal articles, textbooks or other publications related to the Content Outline.
- Attendance at continuing education programs and courses in specialized pharmacy practice.
- Participation in study groups and examination preparation courses.
- Reviewing the sample examination items provided in order for candidates to familiarize themselves with the various item formats which are presented on the exam. Sample question performance should not be interpreted as an indicator of exam performance.
To maintain its strict, independent standards for certification, BPS does NOT provide review information, preparatory courses, or study guides. However, such materials are available from outside organizations, state or local professional associations and colleges of pharmacy. Potential applicants may contact the professional associations noted below for additional study resources.
The Board of Pharmacy Specialties provides the following program listing for informational purposes. This list is not an exhaustive list of options available for examination preparation. BPS does not endorse or provide preparatory courses for Board Certification Examinations.
Cardiology Pharmacy
- American College of Clinical Pharmacy
(913) 492-3311
American Society of Health-System Pharmacists
(866) 279-0681
https://www.rxcertifications.org/Cardiology/Certification-Preparation
BPS partners with Pearson to provide the examination. BPS does not have any other partnerships for the certification or recertification application process. BPS partners with professional development program (PDP) providers to provide continuing pharmacy education (CPE) for recertification and the relationship is noted here. Any organization claiming a relationship with BPS for the application process or providing CPE labeled ‘BPS-approved’ outside of the organizations listed should be reported to BPS immediately.
Certification for Applicants Outside the U.S.
BPS would like to offer some helpful tips to candidates outside of the United States in order to make their application experience easier. To learn more about applying for board certification as a pharmacist outside of the U.S., visit this page.
Apply for ADA Accommodations
BPS complies with the relevant provisions of the Americans with Disabilities Act (ADA). For applicants looking to request special accommodations in their application process, more instructions can be found on this page.
Frequently Asked Questions
After review of the BPS Candidates Guide and specialty certification page, some applicants may still have questions. Visit this page to see frequently asked questions from pharmacists pursuing board certification like you!
Sample Examination Items
Sample Items for BCCP Examinations
The sample examination items for BCCP examinations are made available by BPS for the purposes of familiarizing certification candidates and other stakeholders with the structure and format of BPS Certification Examinations. This is not meant for use as a self-assessment. Performance on any of these items does not correlate with performance on the actual examination.
The content of these examples is meant to be illustrative of actual examination items, but these items do not appear on the certification examination and are not meant to identify the scope of the examination. For a more comprehensive indication of the scope of the certification examination, please refer to the BCCP Exam Content Outline.
Examination items are in multiple-choice format. The great majority of examination items are multiple-choice with a single response from among four options. Some examinations may include a small percentage of items that require selection of multiple (three or four) responses from among a larger set of available (up to eight) options. Examinations items may also be supplemented by an image.
View the examination items down below.
A patient is brought to the emergency department for an acute ischemic stroke. The patient is considered a candidate for thrombolytic therapy, but has a history of uncontrolled hypertension. What blood pressure level must be achieved before an intravenous thrombolytic can be administered?
Correct!
Incorrect!
A primary care physician asks the pharmacist for recommendations to initiate anti-hypertensive therapy for a 60-year-old with a past medical history of hypertension and dyslipidemia. Vital signs consist of a blood pressure of 172/94 mm Hg and a heart rate of 52 bpm.
Notable laboratory values available are:
| SCr | 1.1 mg/dL |
| BUN | 19 mg/dL |
| K | 3.5 mEq/L |
| Na | 138 mEq/L |
| LFTs are within normal limits | |
Which initial strategy would be the best available option for this patient?
Correct!
Incorrect!
A patient with a history of diabetes mellitus, estimated 10-year ASCVD risk of 14.6%, is currently on simvastatin 40 mg daily for the primary prevention of cardiovascular disease. After 6 weeks of therapy, LDL-C is 112 mg/dL (baseline LDL-C was 155 mg/dL). Which intervention is most appropriate?
Correct!
Incorrect!
The nurse manager of a cardiovascular patient care area asks a pharmacist to contribute a medication-related section for the monthly newsletter to the nursing staff. Which would provide the most value?
Correct!
Incorrect!
Which statement regarding the use of intention-to-treat analysis within a prospective, randomized, placebo-controlled clinical trial is accurate?
Correct!
Incorrect!
A clinical trial reports that a chi-square test was used to evaluate data. Which type of data would this test most likely compare?
Correct!
Incorrect!
In a large heart failure prevention trial, the following data were obtained: on placebo, 640 out of 2117 (30.2%) patients developed symptomatic heart failure; on enalapril, 438 out of 2111 (20.7%) patients developed heart failure. What is the number of patients that needed to be treated with enalapril to prevent one case of heart failure?
Correct!
Incorrect!
A patient is being discharged from the hospital on warfarin for treatment of a venous thromboembolism (VTE). What must be documented as a part of the discharge instructions for this patient to meet The Joint Commission standards?
Correct!
Incorrect!
A health system is designing patient education materials focused on the primary prevention of ASCVD among patients with hypertension. The focus of these materials is healthy lifestyle interventions. Which concept should be included in these educational materials?
Correct!
Incorrect!
Share the quiz to show your results !
Subscribe to see your results
I got %%score%% of %%total%% right
Loading...
Recertification Requirements for BCCP
Pharmacists who earn the designation Board-Certified Cardiology Pharmacist (BCCP) are required to maintain their certification over a seven-year period by completing one of the following recertification pathways:
Option One: Recertification Examination
- For BCCP with certification beginning January 1, 2023 or earlier: Achieve a passing score on the recertification examination administered by BPS.
- For BCCP with certification beginning January 1, 2024 or later:Achieve a passing score on the recertification examination administered by BPS and self-report up to 20 units of continuing professional development (CPD). Assessed continuing pharmacy education (CPE) from BPS-approved professional development programs can also satisfy this requirement. For more information on CPD, review the FAQ. To maintain an active certification in good standing, a minimum of two units of assessed CPE from BPS-approved professional development programs or self-reported CPD must be reported each year.
OR
Option Two: Professional Development Program
- BCCP with certification beginning January 1, 2023 or earlier: recertification via professional development program requires 100 units of assessed CPE from BPS-approved professional development programs offered by:
- The American College of Clinical Pharmacy (ACCP) in collaboration with the American Society of Health-System Pharmacists (ASHP).
- BCCP may participate in recertification from any BPS-approved BCCP programs.
- BCCP with certification beginning January 1, 2024 or later: recertification via professional development program requires 100 units. Earn at least 80 units of assessed continuing pharmacy education (CPE) from BPS-approved professional development programs and self-report up to 20 units of continuing professional development (CPD) by the end of the 7 year recertification cycle (assessed CPE can also satisfy this requirement).*
- The American College of Clinical Pharmacy (ACCP) in collaboration with the American Society of Health-System Pharmacists (ASHP).
- * A minimum of 2 units of CPD or BPS-approved, assessed CPE must be earned annually, regardless of recertification pathway
- BCCP may participate in recertification from BPS-approved BCCP programs.
Click here to view a simplified comparison infographic to learn more about the differences between the CPE and CPD recertification frameworks.
| Year certified/recertified | New cycle start (begin earning recert units) | Cycle expiration (deadline to meet recert reqs) | Units required (PDP = professional development program) |
| 2019 | 1/1/2020 | 12/31/2026 | 100 units assessed CPE via BPS-approved PDP |
| 2020 | 1/1/2021 | 12/31/2027 | 100 units assessed CPE via BPS-approved PDP |
| 2021 | 1/1/2022 | 12/31/2028 | 100 units assessed CPE via BPS-approved PDP |
| 2022 | 1/1/2023 | 12/31/2029 | 100 units assessed CPE via BPS-approved PDP |
| 2023 | 1/1/2024 | 12/31/2030 | 100 units (80 units assessed CPE via BPS-approved PDP + 20 units CPD) |
| 2024 onward | 1/1/2025 onward | 12/31/2031 onward | 100 units (80 units assessed CPE via BPS-approved PDP + 20 units CPD) |
For full details regarding recertification, please refer to the BPS Recertification Guide.
Board-Certified Cardiology Pharmacists are required to pay the BPS Annual Certification Maintenance Fee of $125 each year for years one through six and the $400 recertification fee in year seven. Individuals with more than one BPS certification are assessed one BPS Annual Certification Maintenance Fee each year.
Upcoming Deadlines for Recertification
Candidates are required to recertify every 7 years. Certificants must submit their recertification application no later than the deadline of August 17. BPS encourages candidates to submit their recertification application as early as January 1 of their recertification year.
Candidates who intend to recertify via examination should note the availability of the recertification examination and related application deadlines. Candidates recertifying their BCCP® credential by examination can find more information about examination dates and fees here.
Candidates who intend to recertify via continuing pharmacy education (CPE) MUST submit their recertification application by the deadline date of August 17 even if they have not completed their CPE requirements.
The deadline to complete the required CPE for recertification is December 31 for all specialties. The board-certified pharmacist is responsible for submitting an application that is completely and accurately filled out. Incomplete and/or unpaid applications will not be processed.
Recertification Guide
CPE Providers
BCCP with certification beginning January 1, 2023 or earlier: recertification via professional development program requires 100 units of assessed CPE from BPS-approved professional development programs offered by:
BCCP may participate in recertification from any BPS-approved BCCP programs.
BCCP with certification beginning January 1, 2024 or later: recertification via professional development program requires 100 units. Earn at least 80 units of assessed continuing pharmacy education (CPE) from a BPS-approved professional development programs and self-report up to 20 units of continuing professional development (CPD) by the end of the 7 year recertification cycle (assessed CPE can also satisfy this requirement).*
*A minimum of 2 units of CPD or BPS-approved, assessed CPE must be earned annually, regardless of recertification pathway.
BCCP may participate in recertification from any BPS-approved BCCP programs.
Content Outline for BCCP® Examinations
Refer to the Cardiology Pharmacy Examination Content Outline here for details on eligibility requirements, effective dates, and more.
The examination content outline is a product of a job analysis, also known as a role delineation study, that includes discussions with a panel of 15-20 subject matter experts who represent the specialty area. These experts determine the competencies required for safe and effective pharmacy practice in the specialty area and engage board-certified pharmacists through a validation survey for their endorsement of the identified competencies. The job analysis process is conducted every 5 years to help ensure that the competencies in the examination content outline reflect current pharmacy practice in the specialty area.
- Click here to review the 2025 BCCP Job Analysis Summary.
Important Resources
Logging CPD Activities (Video)
Watch a step-by-step video walkthrough of how to report CPD activities in MyBPS once a certificant begins a new certification cycle. For CPD categories and descriptions, see the “How will CPD activities contribute to recertification?” question in the CPD FAQs.
CPD Annual Reflection and Plan (ARP) Sample
Click here to view a sample Annual Reflection and Plan (ARP) to help guide formatting and structure for your CPD annual reflection and learning plan.
CPD Activity Evaluation Sample
Click here to view a sample CPD activity evaluation (scholarly activity) to help guide how evaluations may be documented for CPD credit. This sample is for guidance and is not the only acceptable format.
Frequently Asked Questions
After review of the BPS Recertification Guide and specialty page, some applicants may still have questions. Visit this page to see frequently asked questions from pharmacists renewing their board certification like you!
Sample Examination Items
Sample Items for BCCP Examinations
The sample examination items for BCCP examinations are made available by BPS for the purposes of familiarizing certification candidates and other stakeholders with the structure and format of BPS certification examinations. This is not meant for use as a self-assessment. Performance on any of these items does not correlate with performance on the actual examination.
The content of these examples is meant to be illustrative of actual examination items, but these items do not appear on the certification examination and are not meant to identify the scope of the examination. For a more comprehensive indication of the scope of the certification examination, please refer to the BCCP Exam Content Outline.
Examination items are in multiple-choice format. The great majority of examination items are multiple-choice with a single response from among four options. Some examinations may include a small percentage of items that require selection of multiple (three or four) responses from among a larger set of available (up to eight) options. Examinations items may also be supplemented by an image.
View the examination items down below.
A patient is brought to the emergency department for an acute ischemic stroke. The patient is considered a candidate for thrombolytic therapy, but has a history of uncontrolled hypertension. What blood pressure level must be achieved before an intravenous thrombolytic can be administered?
Correct!
Incorrect!
A primary care physician asks the pharmacist for recommendations to initiate anti-hypertensive therapy for a 60-year-old with a past medical history of hypertension and dyslipidemia. Vital signs consist of a blood pressure of 172/94 mm Hg and a heart rate of 52 bpm.
Notable laboratory values available are:
| SCr | 1.1 mg/dL |
| BUN | 19 mg/dL |
| K | 3.5 mEq/L |
| Na | 138 mEq/L |
| LFTs are within normal limits | |
Which initial strategy would be the best available option for this patient?
Correct!
Incorrect!
A patient with a history of diabetes mellitus, estimated 10-year ASCVD risk of 14.6%, is currently on simvastatin 40 mg daily for the primary prevention of cardiovascular disease. After 6 weeks of therapy, LDL-C is 112 mg/dL (baseline LDL-C was 155 mg/dL). Which intervention is most appropriate?
Correct!
Incorrect!
The nurse manager of a cardiovascular patient care area asks a pharmacist to contribute a medication-related section for the monthly newsletter to the nursing staff. Which would provide the most value?
Correct!
Incorrect!
Which statement regarding the use of intention-to-treat analysis within a prospective, randomized, placebo-controlled clinical trial is accurate?
Correct!
Incorrect!
A clinical trial reports that a chi-square test was used to evaluate data. Which type of data would this test most likely compare?
Correct!
Incorrect!
In a large heart failure prevention trial, the following data were obtained: on placebo, 640 out of 2117 (30.2%) patients developed symptomatic heart failure; on enalapril, 438 out of 2111 (20.7%) patients developed heart failure. What is the number of patients that needed to be treated with enalapril to prevent one case of heart failure?
Correct!
Incorrect!
A patient is being discharged from the hospital on warfarin for treatment of a venous thromboembolism (VTE). What must be documented as a part of the discharge instructions for this patient to meet The Joint Commission standards?
Correct!
Incorrect!
A health system is designing patient education materials focused on the primary prevention of ASCVD among patients with hypertension. The focus of these materials is healthy lifestyle interventions. Which concept should be included in these educational materials?
Correct!
Incorrect!
Share the quiz to show your results !
Subscribe to see your results
I got %%score%% of %%total%% right
Loading...
Testimonials
Certification Verification
BPS offers the ability to search and verify a Board-Certified Pharmacist by name or credential number.